• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Netherlands Pharmaceuticals and Healthcare Report Q2 2008 - Product Image

Netherlands Pharmaceuticals and Healthcare Report Q2 2008

  • Published: May 2008
  • Region: Netherlands, Holland
  • 70 pages
  • Business Monitor International

FEATURED COMPANIES

  • Akzo Nobel
  • Crucell
  • DSM
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Novartis
  • MORE

The Netherlands Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Netherlands pharmaceuticals and healthcare industry.

Growth will be far from impressive for the drug market in the Netherlands over the forecast period, although, in many ways this reflects the general sluggishness seen in mature markets. BMI expects the market to reach a value of US$7.06bn in 2012, representing a compound annual growth rate (CAGR) of
2.08%. Growth will be strongest in the generics market but should also be reasonable for consumer health products as these medicines benefit from government liberalisation policies.

The generics sector, however, will be negatively impacted by the new transition agreement regarding pharmaceutical prices that has come into effect. In January 2008, the price of generic medicines was reduced by 10%. BMI has factored this decrease into our forecasts and believes that the generics market will reach a value of US$1.28bn by 2012. In addition, medicines whose patents expire in 2008 will see price cuts of 50%. The Dutch Pharmacy Association, KNMP, claims that the plans are designed to keep the cost of medicines down. READ MORE >

Executive Summary
Netherlands Pharmaceuticals And Healthcare Industry
Pharmaceutical Business Environment Ratings
Table: Western European Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement
OTC Medicines
Industry Developments
Healthcare Sector
Healthcare Insurance
Table: Key Points - Dutch Health Insurance Act, January 1 2006
Health Profile
Pharmaceuticals Sector
Recent Domestic Companies’ Activities
Recent Foreign Companies’ Activities
Research And Development Sector
Industry Forecast Scenario
Overall Market Forecast
Table: The Netherlands Drug Market Forecast Indicators
Key Growth Factors - Industry
Table: Netherlands Health Expenditure Indicators
Key Growth Factors - Macroeconomic
Table: Netherlands - Macroeconomic Forecasts
Patented Market Forecast
Table: The Netherlands’ Patented Drug Market Forecast Indicators (US$mn unless otherwise stated)
Over-The-Counter Market Forecast
Table: The Netherlands OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated)
Generics Forecasts
Table: The Netherlands’ Generics And Branded Market Forecast Indicators
Export/Import Forecasts
Table: The Netherlands’ Pharmaceutical Trade Forecast Indicators (US$mn)
Key Risks To our Forecast Scenario
Competitive Landscape

Company Profiles

Leading Multinational Manufacturers
- Merck & Co
- Pfizer
- GlaxoSmithKline (GSK)
- Sanofi-Aventis
- Novartis

Indigenous Manufacturers
- Akzo Nobel
- DSM
- Qiagen
- Pharming Group
- Crucell

BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources



- Merck & Co
- Pfizer
- GlaxoSmithKline (GSK)
- Sanofi-Aventis
- Novartis
- Akzo Nobel
- DSM
- Qiagen
- Pharming Group
- Crucell

Note: Product cover images may vary from those shown

ALSO AVAILABLE

RELATED PRODUCTS

Our Clients

Our clients' logos